Atlas Trials

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT02497378 · COMPLETED

Trial details

NCT number
NCT02497378
Sponsor
Janssen Pharmaceutical K.K.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2015-07-10
Primary completion
2018-03-06
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.